Related by context. Frequent words. (Click for all words.) 57 efficacy tolerability 54 ponatinib 54 amrubicin 53 Carfilzomib 53 Zoraxel 53 efficacy endpoint 53 anti leukemic 53 renal toxicity 53 HGS ETR2 53 proteasome inhibitor 53 NEUMUNE 52 Fibrillex TM 52 tanespimycin 52 ganetespib 52 romidepsin 52 PEG SN# 52 Plenaxis R 52 vosaroxin 52 pharmacokinetic profiles 52 elotuzumab 51 teriflunomide 51 BrachySil 51 CYT# 51 indolent NHL 51 ARIKACE 51 pharmacokinetic studies 51 Entereg R 51 TOLAMBA 51 OXi# 51 IIa trial 51 Anthim 51 dosing frequency 51 therapeutic regimens 50 subgroup analyzes 50 Synavive 50 nanoviricide 50 AZX# 50 Phenoptin 50 neuroprotective properties 50 potent antiviral 50 calcineurin inhibitors 50 heavily pretreated 50 tasimelteon 50 zileuton 50 nonclinical studies 50 enzastaurin 50 phase Ib 50 vismodegib 50 ICA # 50 tipranavir 50 vivo efficacy 50 Hepatitis C virus HCV 50 6R BH4 50 efficacy 50 xenograft models 50 preclinical studies 50 bactericidal 50 RGB # 50 PXD# 50 Soliris TM eculizumab 50 sipuleucel T 49 pharmacodynamic 49 secondary efficacy endpoints 49 tezampanel 49 vascular disrupting agent 49 Secondary endpoints include 49 immunomodulating 49 Phase 2b clinical trials 49 TELCYTA 49 iclaprim 49 Alzhemed TM 49 pharmacokinetic parameters 49 nilotinib 49 Aurexis 49 isavuconazole 49 CA4P 49 pharmacokinetic PK 49 squalamine 49 pegylated interferon alpha 49 Mipomersen 49 IND submission 49 Azixa 49 anti TNF biologic 49 PREZISTA r 49 pharmacodynamic effects 48 placebo controlled clinical trials 48 immunological disorders 48 bosutinib 48 receiving VELCADE 48 topical anti infective 48 Poly ICR 48 PROVIGIL 48 MOZOBIL 48 Antihypertensive 48 analgesic efficacy 48 SAR# [004] 48 hematologic cancers 48 phase 2a 48 pharmacoeconomic 48 CR# vcMMAE 48 alagebrium